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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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ISVH SOCIETY NEWS
ASH–ISVH Symposium
As Chairman of the International Society for Vascular Health (ISVH), I am delighted 
to announce the formation of an agreement between ISVH and American Society of 
Hypertension (ASH). A joint ASH–ISVH Symposium will be held during the ASH 
Congress in New Orleans, May 15–16th 2008. This symposium will feature the 
world’s experts in vascular health and will debate the subject of: “Global Challenges 
to Improve Vascular Health Worldwide”.
Full details will be posted shortly on the ISVH website, http://www.isvh.net/ and in 
the next edition of Vascular Health and Risk Management.
China
In June 2007, ISVH held its second China Congress in two cities (Beijing and Tai-
yuan), which attracted over 1000 delegates. The Co-Chairmen were Professors John 
Cockcroft (UK), Kenji Takazawa (Japan), and Hongju Wang (Beijing).
The Beijing Congress was opened by the Chinese Minister of Health and chaired 
by Professor Gong of Shanghai.
Next year, in parallel with the Beijing Olympic Games, ISVH will hold a China 
Week from August 08–15 2008, with Symposia in Shanghai, Beijing, Tibet, and 
Mongolia as well as in mainland China. Over 2,000 doctors are expected to subscribe 
to this ISVH China Week, and we welcome ISVH members from all over the world 
to attend.
Australia
The ﬁ  rst Congress was held in May 2007 in Melbourne, presided by ISVH Vice 
President, Professor James Cameron. Details of this congress and the China Congress 
can be found on the ISVH Website.
A second ISVH Congress will be held in October 2007 in Melbourne, Australia.
New ISVH Regional Committees
ISVH will launch Regional Committees in 2008 in Japan and USA. The Japan ISVH 
will arrange meetings in 2008 and an international meeting in 2010.
ISVH at ESH
ISVH participated in the 2007 annual meeting of the European Society of Hypertension 
(ESH), which was held in Milan, Italy, from 16–18 June, and distributed invitations 
to its forthcoming events.
ISVH and International Guidelines on Vascular 
Health
ISVH will actively participate in International Guidelines on Vascular Health and will 
publish these in the ISVH journal, Vascular Health and Risk Management.
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